Mikael Hartman

Hartman Mikael

Appointment(s)
  • Associate Professor, Department of Surgery, NUS Yong Loo Lin School of Medicine
  • Associate Professor, NUS Saw Swee Hock School of Public Health
  • Senior Consultant, Department of Surgery, National University Health System
Administrative Appointment(s)
  • Director, Research Community, University Surgical Cluster, National University Health System  
Academic Qualifications
  • PhD, Karolinska Institutet, Stockholm, Sweden
  • MD, Karolinska Institutet, Stockholm, Sweden
Research Interest(s)
  • Breast Cancer Etiology
  • Clinical Epidemiology
  • Breast Cancer Prognostication
Recent Publications
  • 1. Wang T, Seah S, Loh X, Chan CW, Hartman M, Goh BC, Lee SC. 2016 Jan. Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway. Oncotarget. 7(3):2532-44. doi: 10.18632/oncotarget.6304. 26565813.
  • 2. Tan J, Ong CK, Lim WK, Ng CC, Thike AA, Ng LM, Rajasegaran V, Myint SS, Nagarajan S, Thangaraju S, Dey S, Nasir ND, Wijaya GC, Lim JQ, Huang D, Li Z, Wong BH, Chan JY, McPherson JR, Cutcutache I, Poore G, Tay ST, Tan WJ, Putti TC, Ahmad BS, Iau P, Chan CW, Tang AP, Yong WS, Madhukumar P, Ho GH, Tan VK, Wong CY, Hartman M, Ong KW, Tan BK, Rozen SG, Tan P, Tan PH, Teh BT. 2015 Nov. Genomic landscapes of breast fibroepithelial tumors. Nat Genet. 47(11):1341-5. doi: 10.1038/ng.3409. 26437033.
  • 3. Guo X, Long J, Zeng C, Michailidou K, Ghoussaini M, Bolla MK, Wang Q, Milne RL, Shu XO, Cai Q, Beesley J, Kar SP, Andrulis IL, Anton-Culver H, Arndt V, Beckmann MW, Beeghly-Fadiel A, Benitez J, Blot W, Bogdanova N, Bojesen SE, Brauch H, Brenner H, Brinton L, Broeks A, Brüning T, Burwinkel B, Cai H, Canisius S, Chang-Claude J, Choi JY, Couch FJ, Cox A, Cross SS, Czene K, Darabi H, Devilee P, Droit A, Dörk T, Fasching PA, Fletcher O, Flyger H, Fostira F, Gaborieau V, García-Closas M, Giles GG, Grip M, Guénel P, Haiman CA, Hamann U, Hartman M, Hollestelle A, Hopper JL, Hsiung CN, Ito H, Jakubowska A, Johnson N, Kabisch M, Kang D, Khan S, Knight JA, Kosma VM, Lambrechts D, Le Marchand L, Li J, Lindblom A, Lophatananon A, Lubinski J, Mannermaa A, Manoukian S, Margolin S, Marme F, Matsuo K, McLean CA, Meindl A, Muir K, Neuhausen SL, Nevanlinna H, Nord S, Olson JE, Orr N, Peterlongo P, Putti TC, Rudolph A, Sangrajrang S, Sawyer EJ, Schmidt MK, Schmutzler RK, Shen CY, Shi J, Shrubsole MJ, Southey MC, Swerdlow A, Teo SH, Thienpont B, Toland AE, Tollenaar RA, Tomlinson IP, Truong T, Tseng CC, van den Ouweland A, Wen W, Winqvist R, Wu A, Yip CH, Zamora MP, Zheng Y, Hall P, Pharoah PD, Simard J, Chenevix-Trench G; kConFab Investigators, Dunning AM, Easton DF, Zheng W. 2015 Nov. Fine-scale mapping of the 4q24 locus identifies two independent loci associated with breast cancer risk. Cancer Epidemiol Biomarkers Prev. 24(11):1680-91. doi: 10.1158/1055-9965.EPI-15-0363. 26354892.
  • 4. Ler SY, Leung CH, Khin LW, Lu GD, Salto-Tellez M, Hartman M, Iau PT, Yap CT, Hooi SC. 2015 Nov. HDAC1 and HDAC2 independently predict mortality in hepatocellular carcinoma by a competing risk regression model in a Southeast Asian population. Oncol Rep. 4(5):2238-50. doi: 10.3892/or.2015.4263. 26352599.
  • 5. Bhoo-Pathy N, Verkooijen HM, Wong FY, Pignol JP, Kwong A, Tan EY, Aishah Taib N, Nei WL, Ho GF, Tan B, Chan P, Lee SC, Hartman M, Yip CH, Dent R. 2015 Nov. Prognostic role of adjuvant radiotherapy in triple-negative breast cancer: A historical cohort study. Int J Cancer. 137(10):2504-12. doi: 10.1002/ijc.29617. 26018878.